| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 06/17/2004 | US20040116502 Treatment of oppositional defiant disorder and conduct disorder with 5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones |
| 06/17/2004 | US20040116497 Chromane derivatives, process for their preparation and their use as antitumor agents |
| 06/17/2004 | US20040116486 Metalloproteinase inhibitors |
| 06/17/2004 | US20040116482 Potassium channel opener |
| 06/17/2004 | US20040116465 Novel compounds |
| 06/17/2004 | US20040116456 Remedies for psychoneurosis |
| 06/17/2004 | US20040116454 Pyrazole compounds useful as protein kinase inhibitors |
| 06/17/2004 | US20040116453 Synthesis and methods of use pyrimidine analogues and derivatives |
| 06/17/2004 | US20040116447 Pyrazolo[3,4-d]pyrimidine derivatives and their use as purinergic receptor antagonists |
| 06/17/2004 | US20040116446 Nitrogen compounds having improved solubility, bioavailability and stability, used as sedatives, anxiolytics, anticonvulsant, and/ or muscle relaxants for prophylaxis of sleep disorders |
| 06/17/2004 | US20040116445 Substituted thioacetamides |
| 06/17/2004 | US20040116444 Psychological disorders, anxiety and stress disorders, antidepressants |
| 06/17/2004 | US20040116443 Dopamine D4 ligands for the treatment of novelty-seeking disorders |
| 06/17/2004 | US20040116442 Novel pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| 06/17/2004 | US20040116441 Antagonist as immunomodulators for cardiovascular disorders, antiinflammatory agents and treatment of other conditions |
| 06/17/2004 | US20040116440 Useful for diagnosis, treatment of male or female sexual dysfunction |
| 06/17/2004 | US20040116439 Serine protease inhibitors |
| 06/17/2004 | US20040116436 Treatment with Brimonidine for nervous system disorders |
| 06/17/2004 | US20040116435 Benzimidazol derivatives modulate chemokine receptors |
| 06/17/2004 | US20040116431 Substituted aryl compounds as novel cyclooxygenase-2 selective inhibitors, compositions and methods of use |
| 06/17/2004 | US20040116424 Aryl imidazoles and related compounds as C5a receptor modulators |
| 06/17/2004 | US20040116423 5-Aryltetrazole compounds, compositions thereof, and uses therefor |
| 06/17/2004 | US20040116416 having immunomodulating and cytokine-release-inhibiting action |
| 06/17/2004 | US20040116415 Aminoalkyl-substituted aryl compounds and their use as sodium channel blockers |
| 06/17/2004 | US20040116406 for the treatment of disorders of the central nervous system such as cerebral, central nervous or psychiatric symptoms, defunctionalization manifestations or disorders which occur as a result of unintentional or intentional intake of psychotropic |
| 06/17/2004 | US20040116405 Use of bicyclic esters or amides for the treatment of diseases responsive to enhanced potassium channel activity |
| 06/17/2004 | US20040116404 Sulphones which modulate the action of gamma secretase |
| 06/17/2004 | US20040116395 Combinations for the treatment of inflammatory disorders |
| 06/17/2004 | US20040116374 C2, 8-disubstituted adenosine derivatives and their different uses |
| 06/17/2004 | US20040116355 Caspase inhibitors and the use thereof |
| 06/17/2004 | US20040116353 Derivatives of n-(arylsulfonyl)beta-aminoacids comprising a substituted aminomethyl group, the preparation method thereof and the pharmaceutical compositions containing same |
| 06/17/2004 | US20040116352 Active substance combination containing a compound with an opioid effect and at least one further compound of formula 1 |
| 06/17/2004 | US20040116342 Therapeutic use of a SMR1-peptide or a pharmaceutically active amount of SMR1-peptide, for the preparation of a therapeutic formulation for preventing or treating diseases wherein a modulation of activity of a membrane metallopeptidase is sought |
| 06/17/2004 | US20040116337 Soluble cyclic analogues of beta amyloid peptide |
| 06/17/2004 | US20040116336 Peptide derivatives |
| 06/17/2004 | US20040115810 Stem cell differentiation-inducing promoter |
| 06/17/2004 | US20040115808 In vitro neuronal stem cell culture for transplantation and treatment of neurodegenerative and gastrointestinal diseases; tissue engineering |
| 06/17/2004 | US20040115807 O-2a progenitors multipotent cells from neurohypophysis |
| 06/17/2004 | US20040115761 Polypeptides and nucleic acids encoding same |
| 06/17/2004 | US20040115331 Suitable for inclusion in food |
| 06/17/2004 | US20040115305 Charging gum base components and all of the chewing gum additives into a mixing apparatus; operating the apparatus at atmospheric pressure to obtain the chewing gum, subject to the limitation that the gum base does not contain a vinyl polyester |
| 06/17/2004 | US20040115263 Administering therapeutically effective amount of bupropion or pharmaceutically acceptable salts thereof |
| 06/17/2004 | US20040115262 Formulations and dosage forms for controlled delivery of topiramate |
| 06/17/2004 | DE10255481A1 Pharmaceutical composition contain hop extract obtained using supercritical fluid, preferably carbon dioxide, useful as sedative |
| 06/17/2004 | CA2508783A1 S-substituted n-1-¬(hetero) aryl|alkyl-n'-¬(hetero)aryl|alkylisothiocarbamides, a method for the preparation of these, physiologically active s-substituted n-1-¬(hetero)aryl|alkyl-n'-¬(hetero)aryl|alkylisothiocarbamides, a pharmaceutical composition and method of treatment |
| 06/17/2004 | CA2508329A1 Substituted dihydrophenanthridinesul fonamides |
| 06/17/2004 | CA2508325A1 Hydroxyethylamine derivatives for the treatment of alzheimer's disease |
| 06/17/2004 | CA2508319A1 Jnk inhibitors |
| 06/17/2004 | CA2508315A1 Aminoalkoxyindoles as 5-ht6-receptor ligands for the treatment of cns-disorders |
| 06/17/2004 | CA2508311A1 The use of 4-phenyl substituted tetrahydroisoquinolines in the treatment of pain, migraine and urinary incontinence |
| 06/17/2004 | CA2507763A1 Fused 1,3-dihydro-imidazole ring compounds |
| 06/17/2004 | CA2507609A1 Method and compositions for treating anxiety |
| 06/17/2004 | CA2507484A1 Substituted ureas and carbamates |
| 06/17/2004 | CA2507395A1 Method for culturing neural stem cells using hepatocyte growth factor |
| 06/17/2004 | CA2507055A1 Treatment of prion-induced diseases by administration of anti-prion antibodies |
| 06/17/2004 | CA2506727A1 Treatment of huntington's disease with epa |
| 06/17/2004 | CA2505783A1 The use of 4-phenyl-substituted tetrahydroisoquinolines in the treatment of pain, migraine headaches and urinary incontinence |
| 06/17/2004 | CA2485957A1 Protease inhibitor |
| 06/17/2004 | CA2414500A1 Agonist-aversive combination medicines |
| 06/16/2004 | WO2004054978A1 Quinoline derivative as diagnostic probe for disease with tau protein accumulation |
| 06/16/2004 | EP1428824A1 Heterocyclic substituted aminoazacycles useful as central nervous system agents |
| 06/16/2004 | EP1428822A2 1-phenylpiperazine derivative as modulators of dopamine neurotransmission |
| 06/16/2004 | EP1428821A1 Piperidin-4-yl amines with analgesic effect |
| 06/16/2004 | EP1428820A1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications |
| 06/16/2004 | EP1428534A1 Benzofurazan derivatives for enhancing glutamatergic synaptic responses |
| 06/16/2004 | EP1428527A1 Novel formulations for transdermal delivery of pergolide |
| 06/16/2004 | EP1427858A2 Specific markers for multiple sclerosis |
| 06/16/2004 | EP1427857A2 Mid 4460, a human tyrosine phosphatase family member and uses therefor |
| 06/16/2004 | EP1427841A2 Nucleic acid-associated proteins |
| 06/16/2004 | EP1427825A2 Cdna encoding the human alpha2 delta4 calcium channel subunit |
| 06/16/2004 | EP1427755A2 Use of peptides comprising post-translational modifications in the treatment of autoimmune pathologies |
| 06/16/2004 | EP1427729A1 Carbazole derivatives and their use as npy5 receptor antagonists |
| 06/16/2004 | EP1427724A1 Novel use of substituted aminomethyl chromans |
| 06/16/2004 | EP1427723A1 Tetrahydropyran derivatives and their use as therapeutic agents |
| 06/16/2004 | EP1427722A2 Pyrrole-type compounds, compositions, and methods for treating cancer, treating viral diseases and causing immunosuppression |
| 06/16/2004 | EP1427720A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427709A1 3-substituted-4-pyrimidone derivatives |
| 06/16/2004 | EP1427708A1 Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them |
| 06/16/2004 | EP1427445A2 Methods of maturing plasmacytoid dendritic cells using immune response modifier molecules |
| 06/16/2004 | EP1427444A2 West nile vaccine |
| 06/16/2004 | EP1427434A2 Anti-inflammatory agent |
| 06/16/2004 | EP1427431A2 Bioadhesive compositions and methods for enhanced mucosal drug absorption |
| 06/16/2004 | EP1427428A2 Apoptosis-mimicking natural vesicles and use thereof in medical treatment |
| 06/16/2004 | EP1427427A1 Derivatives of partially desulphated glycosaminoglycans as heparanase inhibitors, endowed with antiangiogenic activity and devoid of anticoagulating effect |
| 06/16/2004 | EP1427412A1 Methods of treating cytokine mediated diseases |
| 06/16/2004 | EP1427411A2 (-)-1-(3,4-dichlorophenyl)-3-azabicyclo 3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor |
| 06/16/2004 | EP1427407A2 Fatty amine drug conjugates |
| 06/16/2004 | EP1427404A2 Treatment of glial tumors with glutamate antagonists |
| 06/16/2004 | EP1355646A4 Muscarinic receptor agonists |
| 06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 06/16/2004 | EP1339406B1 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |
| 06/16/2004 | EP1315731B1 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
| 06/16/2004 | EP1294364A4 Stable gabapentin having ph within a controlled range |
| 06/16/2004 | EP1282616B1 Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain |
| 06/16/2004 | EP1263751B1 2-phenylpyran-4-one derivatives |
| 06/16/2004 | EP1261344B1 Use of indoloquinoxalines for the treatment of multiple sklerosis |
| 06/16/2004 | EP1255751B1 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors |
| 06/16/2004 | EP1244643B1 Tryptase inhibitors |
| 06/16/2004 | EP1221950B1 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
| 06/16/2004 | EP1214075B1 POLYMORPHS OF N-METHYL-N-(3- 3- 2-THIENYLCARBONYL]-PYRAZOL- 1,5-$g(a)]-PYRIMIDIN-7-YL PHENYL)ACETAMIDE AND COMPOSITIONS AND METHODS RELATED THERETO |